CA Patent

CA3224743A1 — Fusion polypeptides for metabolic disorders

Assigned to Beijing QL Biopharmaceutical Co Ltd · Expires 2023-01-19 · 3y expired

What this patent protects

Provided are conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. Further provided are conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. Pharmaceutical compositions comprising the s…

USPTO Abstract

Provided are conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. Further provided are conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
CA3224743A1
Jurisdiction
CA
Classification
—
Expires
2023-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Beijing QL Biopharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.